Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model
Wang‐Sheng Jin(Army Medical University), Jiaxiang Xiong(Army Medical University), Xin‐Fu Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan‐Jiang Wang(Army Medical University), Xian‐Le Bu(Army Medical University), Weihong Song(Wenzhou Medical University), Huadong Zhou(Army Medical University), Zhian Hu(Allen Institute for Brain Science), Yi-Zheng Wang(Army Medical University), Weiwei Zhang(Army Medical University), Chang‐Yue Gao(Army Medical University), Yani He(PLA Army Engineering University), Sihan Chen(Changchun University of Chinese Medicine), Zhilin Huang(Children's Hospital of Chongqing Medical University), Zhifang Dong(Children's Hospital of Chongqing Medical University), Lin‐Lin Shen(Beijing Anzhen Hospital)
Cited by 125
Related Papers
Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease
|Nature Medicine|2002|768
Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models
|The Journal of Experimental Medicine|2008|363
Activation of β2-adrenergic receptor stimulates γ-secretase activity and accelerates amyloid plaque formation
|Nature Medicine|2006|239
Modifications and Trafficking of APP in the Pathogenesis of Alzheimer’s Disease
|Frontiers in Molecular Neuroscience|2017|161